Check out the interview where she shares her expertise on THC-infused beverages and their effects:

The post McElligott featured in WRAL interview about THC drinks appeared first on Bowles Center for Alcohol Studies.

The post Besheer researching Ozempic’s potential to treat alcohol, opioid addiction appeared first on Bowles Center for Alcohol Studies.

Early findings from the research reveal the severe physiological impact of this mixture, providing crucial insights that could lead to improved treatments for overdoses. This project is part of a broader effort by Triangle CERSI to combat the opioid crisis and highlights the importance of innovative research in tackling such challenges.

聽for more about Dr. Zoe McElligott & Avengers team discovery!

The post Dr. Zoe McElligott and ‘Avengers’ research team make xylazine discovery appeared first on Bowles Center for Alcohol Studies.

BCAS faculty member Leon Coleman, MD, PhD聽has received the聽2025听 from the American Society for Pharmacology and Experimental Therapeutics (ASPET)聽. The ASPET Division for Neuropharmacology established this award to recognize and honor a young independent investigator working in neuropharmacology.

The award recognizes Dr. Coleman鈥檚 his publication quality, research originality, teaching and funding record, patents, and contribution to pharmacology.

Dr. Coleman has a history of making pioneering discoveries in the field of neuropharmacology, particularly alcohol use disorder (AUD) and Alzheimer鈥檚 disease (AD) research. Recently, he has focused on finding novel regulators of immune pathology for alcohol abuse, Alzheimer’s disease, and severe burn injury. Dr. Coleman has found that heavy alcohol use promotes Alzheimer鈥檚 pathology through persistent activation of microglia leading to the disruption of neuronal lipid metabolism. He identified the loss of neuronal lysosomal acid lipase as a fundamental feature of the progression of Alzheimer鈥檚 disease that is enhanced by heavy alcohol use and midlife obesity. This has resulted in a US patent, and the development of novel PET ligands for the early diagnosis of Alzheimer鈥檚 disease. His work has identified extracellular vesicles are fundamental drivers of immune dysfunction in AUD and burn injury. The targeted removal of these detrimental vesicles is now under investigation as a novel immunotherapy approach.

The award will be presented by the Division for Neuropharmacology on April 5, 2025, during the ASPET 2025 Annual Meeting in Portland, Ore. Additionally, Dr. Coleman has been invited to give a lecture on his work as part of the annual meeting.

ASPET聽is a 4,000-member scientific society whose members conduct basic and clinical pharmacological research and work for academia, government, pharmaceutical companies, biotech companies and non-profit organizations. ASPET members work in a variety of different fields and include neuroscientists, toxicologists, chemical biologists, pharmacists, cardiovascular scientists and many more. Though very diverse, our members have a common bond through their membership in ASPET. Members’ research efforts help develop new medicines and therapeutic agents to fight existing and emerging diseases.

The post Coleman wins ASPET Early Career Award appeared first on Bowles Center for Alcohol Studies.

The post Fulton Crews quoted on Good Morning America appeared first on Bowles Center for Alcohol Studies.

Allopregnanolone inhibits binding of lipopolysaccaride (LPS) to it鈥檚 binding site in the binding pocket of the toll-like receptor: Myeloid differentiation factor-2 (TLR4:MD2) protein complex with nanomolar affinity. 聽Such high affinity suggests that endogenous levels of allopregnanolone are sufficient to inhibit inflammatory TLR signaling in healthy humans.

Lopez also found that allopregnanolone blocks other components of the TLR4 activation mechanism in the brain of alcohol-preferring P rats, suggesting this might contribute to its ability to reduce excessive drinking in these rats. 聽The discovery was published in BIomolecules last month:聽 Lopez_Biomolecules_2024.

Lopez is a member of the A. Leslie Morrow Lab.

The post Lopez discovers new mechanism for allopregnanolone inhibition of inflammatory signaling appeared first on Bowles Center for Alcohol Studies.

This cluster hiring initiative builds on Carolina鈥檚 strengths in public health, computational medicine, and neuromodulation. By adding new capacities and analytical methodologies, we are creating a comprehensive, cutting-edge approach to understanding and treating SUD.

黑料网-Chapel Hill聽seeks to hire one individual in each of the following research areas: neuroengineering, biomolecular data science and drug discovery, clinical-translational psychiatry, and health behavior.

Candidates with relevant backgrounds and expertise in any of these areas are encouraged to apply here聽for priority consideration聽by December 15:

The post 黑料网 seeks SUD researchers appeared first on Bowles Center for Alcohol Studies.

The post BCAS Holds Fall Picnic appeared first on Bowles Center for Alcohol Studies.

The post Clinical Trial on Semaglutide Shows Promise for Treatment of Alcohol Use Disorder, Warrants Further Trials appeared first on Bowles Center for Alcohol Studies.

The post Crews Named ‘Highly Ranked Scholar’ in AUD Research appeared first on Bowles Center for Alcohol Studies.